Please assess the completion status of the following clinical trial:

Trial Title: CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study~* Age ≥ 50 years~* Treatment naive AMD patients that are determined to be candidates for ranibizumab~* Visual acuity 20/40 to 20/320~Exclusion Criteria:~* Pregnancy~* Prior enrollment in the study~* Previous therapy for AMD or other retinal diseases which may be used in the treatment of AMD~* Any other condition that the investigator believes would pose a significant hazard to the subject if on-label ranibizumab were prescribed~* Any condition that would interfere with the ERG recording (such as media opacities including lens or corneal opacity)~* Concurrent eye disease in the study eye that could compromise visual acuity (such as diabetic retinopathy, advanced glaucoma)~* Any condition causing the patient to have a significant tremor that would interfere with the patient's ability to remain still during the ERG (such as Parkinson's disease)~* Participation in another simultaneous medical investigation or trial

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).